Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophy
SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics begins second Phase 2 "STORM" clinical trial with regenerative treatment for Fuchs Endothelial Corneal Dystrophy